Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTL0812 in advanced solid tumours
NCT02201823Phase 1Completed
- Sponsor
- AbilityPharma
- Start
- Feb 2014
- Primary completion
- Mar 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrilatazar in solid tumor (advanced stage), sponsored by AbilityPharma. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Feb 2014; status: completed.
02
Drugs
ibrilatazar
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02201823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201823.